Moderna

Rothschild Redburn downgrades Moderna $MRNA to Sell with an $81 PT. The firm calls the Phase 3 melanoma vaccine result “a great result,” but says the stock now appears to price in broad use across multiple tumor types where there is still little or no supporting data

Reading trades.